αAllAboutAminos
Subscribe
≡
Weight regain now has a timetable — and a Nature mouse study tests the limits of semaglutide enthusiasm
Read the Sunday Brief →

The Sunday Brief · Issue №36 · September 6, 2026

Weight regain now has a timetable — and a Nature mouse study tests the limits of semaglutide enthusiasm

5 min read · Week of August 31 – September 6, 2026

The most useful number this week is a rate: about one kilogram per month. That is how fast body weight returns after stopping semaglutide or tirzepatide, according to a meta-analysis pooling six studies and 1,776 participants — half the lost weight back by roughly 7.5 months, and the starting weight by about 15. For anyone modeling these drugs as a finite course rather than an open-ended commitment, this is the clearest timetable published so far.

This digest is editorial synthesis of publicly available research and community discussion. It is not medical advice and does not constitute a recommendation to use any compound. Our methodology →
§1

Research Spotlight: the GLP-1 evidence base quantifies its own limits

A mature week for GLP-1 evidence: the strongest new human data quantify limits rather than benefits — how fast weight returns after discontinuation, and how modest the average quality-of-life gain is despite large weight loss. Alongside that, an Indian-made semaglutide matched the original in a randomized trial, and tirzepatide's liver-fat effect held across a key genetic risk variant. The one animal study of the week, in Nature, is drawing the most attention — and needs the most calibration.

  • After the last dose: pooled data put weight regain at roughly 1 kg per month

    A meta-analysis pooling six studies and 1,776 participants modeled body weight after discontinuation of semaglutide or tirzepatide. From an average 15 kg loss at the point of stopping, regain ran roughly 1 kg per month — half the lost weight back by about 7.5 months, and the starting weight by about 15. Tirzepatide looked numerically faster to regain than semaglutide, but the difference did not hold up after adjustment.

  • Indian-made semaglutide matches the original in a phase 3 head-to-head trial

    In the WIN-IND phase 3 randomized non-inferiority trial, 217 adults in India with type 2 diabetes inadequately controlled on metformin received either a locally made semaglutide (from Intas) or the original Novo Nordisk product for 24 weeks. Both groups saw similar HbA1c reductions of about 1.5 percentage points, comparable changes in blood glucose, body weight, and BMI, and comparable side-effect patterns. The result matters mainly for drug pricing and access in India.

  • Tirzepatide's liver-fat reduction holds regardless of a key fatty-liver gene variant

    The PNPLA3 I148M variant raises the risk of fatty liver disease. In a post hoc analysis of the randomized SURPASS-3 MRI trial, tirzepatide reduced liver fat, body weight, and blood sugar over 52 weeks whether or not participants carried the variant — a finding that suggests the effect is not gated by this piece of genetic risk.

  • Semaglutide's quality-of-life gains are real but smaller than patients can feel

    A meta-analysis pooled quality-of-life data from four STEP trials of weekly semaglutide 2.4 mg, covering about 4,200 adults with overweight or obesity. Patient-reported physical functioning improved versus placebo, but the average gain — 1.71 points on a standard survey — fell short of the 3.7-point threshold considered noticeable to an individual patient. In short: the weight loss is large; the average day-to-day functional change people report is modest.

  • Signal vs. noise: late-life semaglutide extended lifespan — in female mice

    In a Nature study, female mice started on semaglutide at 20 months old — late middle age for a mouse — held onto physical and cognitive function better than controls and lived longer, with effects closely resembling calorie restriction and somewhat better results on exploratory drive, spatial memory, and glucose control. This is drawing heavy community attention, but it is a preclinical animal study: there are no human data on semaglutide and lifespan, and mouse longevity findings have a long record of not carrying over to people. Read it as a hypothesis, not a result to act on.

§2

Community Watch: dose checks and stack logic

Growth-hormone secretagogue stacks — CJC-1295 with ipamorelin in particular — dominated the week's discussion, mostly as dose sanity checks rather than results reports. These are anecdotal community reports around reported protocols, not evidence of any kind; read them as a map of what people are experimenting with and uncertain about, not of what works.

One thing to think about

The week's tension is worth sitting with: in humans, semaglutide's weight effects begin unwinding within months of the last dose, while in aged female mice a late-life course extended lifespan. Whether a drug whose human benefits appear to require continuous use can produce durable aging effects is precisely the question the coming human data will have to answer.

← All issues

Get the next issue

Subscribe to The Sunday Brief

Every Sunday: what the studies say, what the community is finding, and which vendors are credible — straight to your inbox.

Free. Unsubscribe anytime. No affiliate links. No spam.